Three More Join Viatris In Dealing Out Of US Ozempic Patent Challenge
US Patent Trial and Appeal Board Told To Terminate Investigations Of Semaglutide Patent
In the space of a few days, all four generics manufacturers that had successfully petitioned for a re-examination of a key patent shielding Novo Nordisk’s mega blockbuster Ozempic have reached settlement agreements terminating their challenges.
